Low Incidence of Procedure-Related Major Adverse Cardiac Events After Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy

被引:32
|
作者
Veselka, Josef [1 ,2 ]
Lawrenz, Thorsten [3 ,4 ]
Stellbrink, Christoph [3 ,4 ]
Zemanek, David [1 ,2 ]
Branny, Marian
Januska, Jaroslav [5 ]
Groch, Ladislav [6 ]
Dimitrow, Pawel [7 ]
Krejci, Jan [8 ]
Dabrowski, Maciej [9 ]
Mizera, Stanislav [10 ]
Kuhn, Horst [3 ,4 ]
机构
[1] Charles Univ Prague, Med Sch 2, Dept Cardiol, Prague, Czech Republic
[2] Univ Hosp Motol, Prague, Czech Republic
[3] Univ Witten Herdecke, Klinikum Bielefeld Mitte, Dept Cardiol & Internal Intens Care, Bielefeld, Germany
[4] Univ Witten Herdecke, Dept Cardiol, Witten, Germany
[5] Podlesi Hosp, Dept Cardiol, Trinec, Czech Republic
[6] Hosp Pleven, Dept Cardiol, Pleven, Bulgaria
[7] Jagiellonian Univ, Coll Med, Dept Cardiol 2, Krakow, Poland
[8] St Annes Univ Hosp, Int Clin Res Ctr, Dept Internal Med Cardioangiol 1, Brno, Czech Republic
[9] Inst Cardiol, Dept Intervent Cardiol & Angiol, Warsaw, Poland
[10] Natl Inst Cardiovasc Dis, Dept Cardiol, Bratislava, Slovakia
关键词
COMPLETE HEART-BLOCK; TRANSCORONARY ABLATION; DELAYED OCCURRENCE; ETHANOL; SURVIVAL; COMPLICATIONS; MULTICENTER; PREDICTORS; REDUCTION; THERAPY;
D O I
10.1016/j.cjca.2013.04.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Alcohol septal ablation (ASA) is a catheter-based intervention that has been used as an alternative to surgical myectomy in highly symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). However, clinically relevant complications can result, including death and complete heart block (CHB) associated with syncope or resuscitation. This study was designed to evaluate the incidence of major ASA-related adverse cardiac events. Methods: This international multicentre retrospective study included 421 patients in 8 European centres who were treated using ASA from April 1998 to January 2011. Clinical and echocardiographic follow-up (3-6 months) was completed in 394 patients (94%). Results: ASA led to a significant reduction in symptoms and outflow gradients, with 0.7% mortality. A total of 70 patients (17%) experienced mostly transient CHB during and after the procedure; in 30% of them, CHB occurred or recurred later than 24 hours after ASA. Ninety-seven percent of CHB occurred up to the fifth day after ASA. Permanent pacemakers for CHB were implanted in 35 patients (8%). Multivariate analysis identified intraprocedural bundle branch block and age as independent predictors of CHB. Conclusions: The results of the multicentre study demonstrate that ASA appears safe and efficacious, with low early mortality. The most frequent major complication after ASA was CHB (17%), which occurred late or was recurrent in almost one-third of these patients; 8% of patients required permanent pacemaker implantation. Independent predictors of CHB development were intraprocedural bundle branch block and age. Difficulty in predicting CHB should lead to close post-procedural monitoring and hospital stays lasting at least 5 days.
引用
收藏
页码:1415 / 1421
页数:7
相关论文
共 50 条
  • [11] Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy A Word of Balance
    Sorajja, Paul
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (04) : 489 - 494
  • [12] Septal alcohol ablation in hypertrophic obstructive cardiomyopathy: A retrospective analysis
    Yavuzgil, Oguz
    Tuluce, Kamil
    Simsek, Evrim
    Gurgun, Cemil
    Kultursay, Hakan
    Payzin, Serdar
    Hasdemir, Can
    Can, Levent Hurkan
    Turkoglu, Cuneyt
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2012, 20 (03): : 427 - 433
  • [13] Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis
    Osman, Mohammed
    Kheiri, Babikir
    Osman, Khansa
    Barbarawi, Mahmoud
    Alhamoud, Hani
    Alqahtani, Fahad
    Alkhouli, Mohamad
    CLINICAL CARDIOLOGY, 2019, 42 (01) : 190 - 197
  • [14] How Symptomatic Should a Hypertrophic Obstructive Cardiomyopathy Patient Be to Consider Alcohol Septal Ablation?
    Jones, Brandon M.
    Krishnaswamy, Amar
    Smedira, Nicholas G.
    Desai, Milind Y.
    Tuzcu, E. Murat
    Kapadia, Samir R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (05):
  • [15] Update on alcohol septal ablation for hypertrophic obstructive cardiomyopathy
    Veselka, Josef
    Polakova, Eva
    Bonaventura, Jiri
    KARDIOLOGIA POLSKA, 2019, 77 (02) : 160 - 161
  • [16] Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
    Scholtz, Smita
    Rudolph, Volker
    Reil, Jan-Christian
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
  • [17] Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: A comparison with medical therapy
    Li, Peijin
    Xue, Yuguo
    Sun, Jiejun
    Chen, Maolin
    Yu, Xianpeng
    Zhao, Hua
    Gao, Yuechun
    Zhang, Xiaoling
    Jiang, Tengyong
    He, Jiqiang
    CLINICAL CARDIOLOGY, 2021, 44 (10) : 1409 - 1415
  • [18] Early Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A European Multicenter and Multinational Study
    Veselka, Josef
    Lawrenz, Thorsten
    Stellbrink, Christoph
    Zemanek, David
    Branny, Marian
    Januska, Jaroslav
    Sitar, Jan
    Dimitrow, Pawel
    Krejci, Jan
    Dabrowski, Maciej
    Mizera, Stanislav
    Bartel, Thomas
    Kuhn, Horst
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2014, 84 (01) : 101 - 107
  • [19] Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring
    Bleszynski, Peter A.
    Goldenberg, Ilan
    Fernandez, Genaro
    Howell, Erik
    Younis, Arwa
    Chen, Anita Y.
    McNitt, Scott
    Bruckel, Jeffrey
    Ling, Fred
    Cove, Chris
    Aktas, Mehmet K.
    HEART RHYTHM, 2021, 18 (01) : 50 - 56
  • [20] Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
    Noseworthy, Peter A.
    Rosenberg, Michael A.
    Fifer, Michael A.
    Palacios, Igor F.
    Lowry, Patricia A.
    Ruskin, Jeremy N.
    Sanborn, Danita M.
    Picard, Michael H.
    Vlahakes, Gus J.
    Mela, Theofanie
    Das, Saumya
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (01) : 128 - 132